Literature DB >> 19259782

Leukocyte perturbation associated with Fabry disease.

P Rozenfeld1, E Agriello, N De Francesco, P Martinez, C Fossati.   

Abstract

Fabry disease is an X-linked lysosomal storage disorder of glycosphingolipid catabolism due to the deficient activity of the enzyme alpha-galactosidase A. The non-degraded substrate, mainly globotriaosylceramide (Galα1-4Galβ1-4Glcβ1-1Cer; Gb(3)) accumulates progressively in the lysosome of various cells. The aim of this work was to analyse changes in leukocyte subpopulations and surface markers and to determine whether Gb(3) is increased in leukocytes of patients with untreated and treated Fabry disease. Blood samples obtained from 22 male Fabry patients (11 untreated and 11 on enzyme replacement therapy) and 22 normal controls were subjected to flow cytometric analysis of Gb(3) intracellular content, leukocyte subpopulations and cell markers. Based on the fluorescence intensity of bound monoclonal antibody, and relative to normal control leukocytes, Gb(3) appeared significantly increased in lymphocytes (but not in monocytes or granulocytes) from patients with Fabry disease. A significantly higher percentage of lymphocytes and CD19(+) cells and a reduced proportion of monocytes, CD8(+) cells and myeloid dendritic cells were detected in samples from Fabry patients compared with normal controls. CD1d expression was significantly lower and MHC class II surface expression was significantly higher in monocytes from Fabry patients than in normal controls. As previously observed for other adhesion molecules, the expression of CD31 (PECAM) was higher in leukocytes from Fabry patients. In conclusion, the differences recorded in this study reveal a leukocyte perturbation associated with the disease state in Fabry patients, whereas some abnormalities are less marked in treated patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259782     DOI: 10.1007/s10545-009-1060-9

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  36 in total

1.  IgA nephropathy in two adolescent sisters heterozygous for Fabry disease.

Authors:  Catharina Whybra; Andreas Schwarting; Jörg Kriegsmann; Andreas Gal; Eugen Mengel; Christoph Kampmann; Frank Baehner; Ellen Schaefer; Michael Beck
Journal:  Pediatr Nephrol       Date:  2006-07-13       Impact factor: 3.714

2.  Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses.

Authors:  C M Simonaro; M E Haskins; E H Schuchman
Journal:  Lab Invest       Date:  2001-09       Impact factor: 5.662

3.  Gaucher's disease with monoclonal gammopathy. Significance of splenic plasmacytosis.

Authors:  J P Marie; M Tulliez; V Tricottet-Paczinski; M Reynes; J Diebold
Journal:  Scand J Haematol       Date:  1982-01

4.  Characterization of antibodies against ceramidetrihexoside and globoside.

Authors:  M N Hamers; W E Donker-Koopman; M J Coulon-Morelec; P Dupouey; J M Tager
Journal:  Immunochemistry       Date:  1978-06

5.  Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency.

Authors:  R O Brady; A E Gal; R M Bradley; E Martensson; A L Warshaw; L Laster
Journal:  N Engl J Med       Date:  1967-05-25       Impact factor: 91.245

6.  Dendritic cells in patients with type I Gaucher disease are decreased in number but functionally normal.

Authors:  I Micheva; T Marinakis; C Repa; A Kouraklis-Symeonidis; V Vlacha; N Anagnostopoulos; N Zoumbos; A Symeonidis
Journal:  Blood Cells Mol Dis       Date:  2006-03-13       Impact factor: 3.039

7.  Differential alteration of lipid antigen presentation to NKT cells due to imbalances in lipid metabolism.

Authors:  Jens Schümann; Federica Facciotti; Luigi Panza; Mario Michieletti; Federica Compostella; Anthony Collmann; Lucia Mori; Gennaro De Libero
Journal:  Eur J Immunol       Date:  2007-06       Impact factor: 5.532

8.  High incidence of autoantibodies in Fabry disease patients.

Authors:  P Martinez; M Aggio; P Rozenfeld
Journal:  J Inherit Metab Dis       Date:  2007-04-24       Impact factor: 4.982

9.  Fabry's disease: alpha-galactosidase deficiency.

Authors:  J A Kint
Journal:  Science       Date:  1970-02-27       Impact factor: 47.728

10.  An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells.

Authors:  P Dellabona; E Padovan; G Casorati; M Brockhaus; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  9 in total

1.  Innate and Adaptive Immune Response in Fabry Disease.

Authors:  Wladimir Mauhin; Olivier Lidove; Elisa Masat; Federico Mingozzi; Kuberaka Mariampillai; Jean-Marc Ziza; Olivier Benveniste
Journal:  JIMD Rep       Date:  2015-02-18

Review 2.  Pathology and pathogenic pathways in fabry nephropathy.

Authors:  Sandro Feriozzi; Paula Rozenfeld
Journal:  Clin Exp Nephrol       Date:  2021-03-26       Impact factor: 2.801

3.  Fabry disease: characterisation of the plasma proteome pre- and post-enzyme replacement therapy.

Authors:  Sun Hee Heo; Eungu Kang; Yoon-Myung Kim; Heounjeong Go; Kyung Yong Kim; Jae Yong Jung; Minji Kang; Gu-Hwan Kim; Jae-Min Kim; In-Hee Choi; Jin-Ho Choi; Sung-Chul Jung; Robert J Desnick; Han-Wook Yoo; Beom Hee Lee
Journal:  J Med Genet       Date:  2017-08-23       Impact factor: 6.318

Review 4.  From Lysosomal Storage Diseases to NKT Cell Activation and Back.

Authors:  Cátia S Pereira; Helena Ribeiro; M Fatima Macedo
Journal:  Int J Mol Sci       Date:  2017-02-25       Impact factor: 5.923

5.  Corneal confocal microscopy detects corneal nerve damage and increased dendritic cells in Fabry disease.

Authors:  Gulfidan Bitirgen; Kultigin Turkmen; Rayaz A Malik; Ahmet Ozkagnici; Nazmi Zengin
Journal:  Sci Rep       Date:  2018-08-16       Impact factor: 4.379

6.  Fabry disease patients have an increased risk of stroke in the COVID-19 ERA. A hypothesis.

Authors:  R C Reisin; P Rozenfeld; P Bonardo
Journal:  Med Hypotheses       Date:  2020-09-17       Impact factor: 1.538

Review 7.  Potential Role of Sphingolipidoses-Associated Lysosphingolipids in Cancer.

Authors:  Patricia Dubot; Leonardo Astudillo; Nicole Therville; Lorry Carrié; Magali Pettazzoni; David Cheillan; Jérôme Stirnemann; Thierry Levade; Nathalie Andrieu-Abadie; Frédérique Sabourdy
Journal:  Cancers (Basel)       Date:  2022-10-05       Impact factor: 6.575

Review 8.  Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.

Authors:  Björn Hoffmann
Journal:  Orphanet J Rare Dis       Date:  2009-10-11       Impact factor: 4.123

9.  Increased Serum Interleukin-6 and Tumor Necrosis Factor Alpha Levels in Fabry Disease: Correlation with Disease Burden.

Authors:  Nilton Salles Rosa Neto; Judith Campos de Barros Bento; Valéria de Falco Caparbo; Rosa Maria Rodrigues Pereira
Journal:  Clinics (Sao Paulo)       Date:  2021-07-16       Impact factor: 2.365

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.